Physician profile
Muhammed Fa Ali
NPI 1710996194
$46,803.01
in general payments reported to CMS, 2019-2025
30 companies · $3,386 in 2025
The $3,386 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,480 · 2020: $1,884 · 2021: $1,510 · 2022: $8,348 · 2023: $13K · 2024: $11K · 2025: $3,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $16K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $16,412.36 |
| Food and Beverage | $11,167.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17,875.27 | 2019-2025 | Aveir, Ensite, Gallant |
| Biotronik INC. | $9,486.02 | 2019-2024 | Acticor 7 Vr-T Dx, Selectra, Edora 8 Dr-T |
| Medtronic, INC. | $8,495.85 | 2022-2025 | Micra, Azure Xt Dr Mri Surescan, Selectsecure |
| Boston Scientific Corporation | $4,325.56 | 2021-2025 | Farapulse, Watchman Flx, Watchman Access System |
| Medtronic Vascular, INC. | $3,660.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $718.78 | 2020-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $330.34 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $305.70 | 2019-2024 | Xarelto |
| Philips North America LLC | $281.66 | 2019-2024 | (Am5) Lead Management |
| Astrazeneca Pharmaceuticals LP | $202.14 | 2021-2024 | Farxiga, Lynparza |
| Abiomed | $153.57 | 2023-2025 | Impella |
| Merck Sharp & Dohme LLC | $139.53 | 2022-2025 | Verquvo |
| Novo Nordisk INC | $124.61 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Biosense Webster, INC. | $119.58 | 2021 | |
| Edwards Lifesciences Corporation | $113.20 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $110.00 | 2024-2025 | Repatha, Repatha |
| Pfizer INC. | $83.32 | 2019-2025 | |
| Cook Medical LLC | $38.77 | 2022 | |
| Inspire Medical Systems, INC. | $35.25 | 2023 | Inspire |
| Lilly USA, LLC | $32.50 | 2021-2025 | Zepbound |
| Amarin Pharma, INC. | $22.07 | 2020 | |
| Cardiva Medical, INC. | $21.92 | 2021 | |
| Cordis US Corp. | $21.23 | 2025 | Mynx Control Venous |
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.44 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.12 | 2021 | |
| Cranial Technologies, INC | $14.31 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $13.99 | 2024 | Crysvita |
| Medtronic USA, INC. | $13.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.